 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
CLINICAL SCIENCE |
,
,
From the Sections of *General Internal Medicine and Cardiology, San Francisco Veterans Affairs Medical Center, and the Departments of Medicine, Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California; and the Section of Cardiovascular Medicine, Department of Internal Medicine, and the ¶Section of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut
Correspondence to Dr. Michael G. Shlipak, General Internal Medicine Section, VA Medical Center (111A1), 4150 Clement Street, San Francisco, CA 94121. Phone: 415-221-4810 x3377; Fax: 415-379-5573; E-mail: shlip{at}itsa.ucsf.edu
ABSTRACT. Renal dysfunction is a common complication for patients with heart failure, but its association with clinical outcomes has not been fully characterized. We evaluated the association of glomerular filtration rate (GFR) with heart failure survival and the effect of digoxin on heart failure outcomes across GFR strata. A secondary analysis from the Digitalis Intervention Group trial was conducted of 6800 outpatients with systolic heart failure. Renal function was categorized as estimated GFR (expressed in ml/min per 1.73 m2). All-cause mortality (mean, 3 yr) was inversely proportional to GFR (GFR >60, 31% mortality; GFR 30 to 60, 46% mortality; GFR <30, 62% mortality; P < 0.001). Among patients with a GFR <50, lower GFR were associated with greater adjusted mortality risk (GFR <30: hazard ratio [HR], 2.06, 95% confidence interval [CI], 1.69 to 2.51; GFR 30 to 40: HR, 1.42, 95% CI, 1.22 to 1.67; GFR 40 to 50: HR, 1.22, 95% CI, 1.07 to 1.39; GFR 50 to 60: HR, 1.00, referent). In contrast, participants with GFR 60 to 70 had similar risk (HR, 1.00; 95% CI, 0.88 to 1.14) compared with GFR 50 to 60, and those with GFR >70 had a slightly lower mortality hazard (0.89; 95% CI, 0.78 to 1.00). Linear spline analyses confirmed that GFR = 50 was the appropriate risk threshold; above 50, GFR had no association with mortality, whereas below 50, mortality risk increased sharply with declining GFR (spline coefficient, P < 0.0001). Digoxin efficacy did not differ by level of GFR (P = 0.19 for interaction). Renal dysfunction is strongly associated with mortality in stable outpatients with heart failure, notably in patients with estimated GFR <50 ml/min per 1.73 m2. The effect of digoxin did not differ by level of renal function.
Related Article
J. Am. Soc. Nephrol. 2004 15: 1967-1970.
This article has been cited by other articles:
 |
|
 |
|
  R. C. Campbell, X. Sui, G. Filippatos, T. E. Love, C. Wahle, P. W. Sanders, and A. Ahmed Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study Nephrol. Dial. Transplant., January 1, 2009; 24(1): 186 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Saran and T. D. DuBose Jr Cardiovascular disease in chronic kidney disease Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 425 - 434. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Bittl Damage Control for Renal Artery Stenting Circulation, May 27, 2008; 117(21): 2724 - 2726. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nohria, V. Hasselblad, A. Stebbins, D. F. Pauly, G. C. Fonarow, M. Shah, C. W. Yancy, R. M. Califf, L. W. Stevenson, and J. A. Hill Cardiorenal Interactions: Insights From the ESCAPE Trial J. Am. Coll. Cardiol., April 1, 2008; 51(13): 1268 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schernthaner Kidney disease in diabetology: lessons from 2007 Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1112 - 1115. [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Smith, F. A. Masoudi, M. G. Shlipak, H. M. Krumholz, and C. R. Parikh Renal Impairment Predicts Long-Term Mortality Risk after Acute Myocardial Infarction J. Am. Soc. Nephrol., January 1, 2008; 19(1): 141 - 150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Schneider, E. Ferrannini, R. DeFronzo, G. Schernthaner, J. Yates, and E. Erdmann Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 182 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Phillips, A. Kashani, D. K. Ko, G. Francis, and H. M. Krumholz Adverse Effects of Combination Angiotensin II Receptor Blockers Plus Angiotensin-Converting Enzyme Inhibitors for Left Ventricular Dysfunction: A Quantitative Review of Data From Randomized Clinical Trials Arch Intern Med, October 8, 2007; 167(18): 1930 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Bauman, R. J. DiDomenico, M. Viana, and M. Fitch A Method of Determining the Dose of Digoxin for Heart Failure in the Modern Era Arch Intern Med, December 11, 2006; 166(22): 2539 - 2545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Coca, H. M. Krumholz, A. X. Garg, and C. R. Parikh Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA, September 20, 2006; 296(11): 1377 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonelli, N. Wiebe, B. Culleton, A. House, C. Rabbat, M. Fok, F. McAlister, and A. X. Garg Chronic Kidney Disease and Mortality Risk: A Systematic Review J. Am. Soc. Nephrol., July 1, 2006; 17(7): 2034 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Smith, M. G. Shlipak, E. P. Havranek, J. M. Foody, F. A. Masoudi, S. S. Rathore, and H. M. Krumholz Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med, May 22, 2006; 166(10): 1134 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Smith, J. H. Lichtman, M. B. Bracken, M. G. Shlipak, C. O. Phillips, P. DiCapua, and H. M. Krumholz Renal Impairment and Outcomes in Heart Failure: Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1987 - 1996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Shlipak, M. J. Sarnak, R. Katz, L. F. Fried, S. L. Seliger, A. B. Newman, D. S. Siscovick, and C. Stehman-Breen Cystatin C and the Risk of Death and Cardiovascular Events among Elderly Persons N. Engl. J. Med., May 19, 2005; 352(20): 2049 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Smith, M. G. Shlipak, E. P. Havranek, F. A. Masoudi, W. M. McClellan, J. M. Foody, S. S. Rathore, and H. M. Krumholz Race and Renal Impairment in Heart Failure: Mortality in Blacks Versus Whites Circulation, March 15, 2005; 111(10): 1270 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bibbins-Domingo, F. Lin, E. Vittinghoff, E. Barrett-Connor, D. Grady, and M. G. Shlipak Renal insufficiency as an independent predictor of mortality among women with heart failure J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1593 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
